{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:33:31Z","timestamp":1790202811185,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Apsen Farmaceutica SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03275-8","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:38:53Z","timestamp":1751517533000},"page":"4161-4187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Trospium Chloride in the Treatment of Overactive Bladder Syndrome and Detrusor Overactivity"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-0577","authenticated-orcid":false,"given":"Jos\u00e9 C.","family":"Truzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-6076","authenticated-orcid":false,"given":"Marair G. F.","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-8542","authenticated-orcid":false,"given":"Vitorio L.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"3275_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003088-200544070-00003\/METRICS","volume":"44","author":"O Doroshyenko","year":"2005","unstructured":"Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44:701\u201320. https:\/\/doi.org\/10.2165\/00003088-200544070-00003\/METRICS.","journal-title":"Clin Pharmacokinet"},{"key":"3275_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/J.JURO.2007.05.058","volume":"178","author":"D Staskin","year":"2007","unstructured":"Staskin D, Sand P, Zinner N, Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase\u00a0III trial. J Urol. 2007;178:978\u201384. https:\/\/doi.org\/10.1016\/J.JURO.2007.05.058.","journal-title":"J Urol"},{"key":"3275_CR3","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/NAU.25037","volume":"41","author":"J Zillioux","year":"2022","unstructured":"Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41:1928\u201333. https:\/\/doi.org\/10.1002\/NAU.25037.","journal-title":"Neurourol Urodyn"},{"key":"3275_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/J.EURURO.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543\u201362. https:\/\/doi.org\/10.1016\/J.EURURO.2008.06.047.","journal-title":"Eur Urol"},{"key":"3275_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/J.1365-2125.2011.03961.X","volume":"72","author":"E Callegari","year":"2011","unstructured":"Callegari E, Malhotra B, Bungay PJ, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72:235\u201346. https:\/\/doi.org\/10.1111\/J.1365-2125.2011.03961.X.","journal-title":"Br J Clin Pharmacol"},{"key":"3275_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/S40266-015-0301-X","volume":"32","author":"SC McFerren","year":"2015","unstructured":"McFerren SC, Gomelsky A. Treatment of overactive bladder in the elderly female: the case for trospium, oxybutynin, fesoterodine and darifenacin. Drugs Aging. 2015;32:809\u201319. https:\/\/doi.org\/10.1007\/S40266-015-0301-X.","journal-title":"Drugs Aging"},{"key":"3275_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/S40266-023-01009-5","volume":"40","author":"A Ganguly","year":"2023","unstructured":"Ganguly A, Tyagi S, Chermansky C, et al. Treating lower urinary tract symptoms in older adults: intravesical options. Drugs Aging. 2023;40:241\u201361. https:\/\/doi.org\/10.1007\/S40266-023-01009-5.","journal-title":"Drugs Aging"},{"key":"3275_CR8","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/J.1742-1241.2010.02493.X","volume":"64","author":"C Chapple","year":"2010","unstructured":"Chapple C. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract. 2010;64:1535\u201340. https:\/\/doi.org\/10.1111\/J.1742-1241.2010.02493.X.","journal-title":"Int J Clin Pract"},{"key":"3275_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12894-018-0394-8\/FIGURES\/5","volume":"18","author":"A Ivchenko","year":"2018","unstructured":"Ivchenko A, B\u00f6deker RH, Neumeister C, Wiedemann A. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study. BMC Urol. 2018;18:1\u201313. https:\/\/doi.org\/10.1186\/S12894-018-0394-8\/FIGURES\/5.","journal-title":"BMC Urol"},{"key":"3275_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/pharmrev.121.000523","volume":"75","author":"MC Michel","year":"2023","unstructured":"Michel MC, Cardozo L, Chermansky CJ, et al. Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. 2023;75:554\u2013674. https:\/\/doi.org\/10.1124\/pharmrev.121.000523.","journal-title":"Pharmacol Rev"},{"key":"3275_CR11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1517\/14656566.6.8.1409","volume":"6","author":"NR Zinner","year":"2005","unstructured":"Zinner NR. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother. 2005;6:1409\u201320. https:\/\/doi.org\/10.1517\/14656566.6.8.1409.","journal-title":"Expert Opin Pharmacother"},{"key":"3275_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/S003450100225\/METRICS","volume":"19","author":"K H\u00f6fner","year":"2001","unstructured":"H\u00f6fner K, Oelke M, Machtens S, Gr\u00fcnewald V. Trospium chloride\u2014an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol. 2001;19:336\u201343. https:\/\/doi.org\/10.1007\/S003450100225\/METRICS.","journal-title":"World J Urol"},{"key":"3275_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1055\/S-0031-1300230\/BIB","volume":"50","author":"S \u00dcckert","year":"2000","unstructured":"\u00dcckert S, Stief CG, Odenthal KP, Truss MC, Lietz B, Jonas U. Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder. Arzneimittel-Forschung Drug Res. 2000;50:456\u201360. https:\/\/doi.org\/10.1055\/S-0031-1300230\/BIB.","journal-title":"Arzneimittel-Forschung Drug Res"},{"key":"3275_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/S11934-003-0023-1\/METRICS","volume":"4","author":"RW Pak","year":"2003","unstructured":"Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep. 2003;4:436\u201340. https:\/\/doi.org\/10.1007\/S11934-003-0023-1\/METRICS.","journal-title":"Curr Urol Rep"},{"key":"3275_CR15","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2165\/00003495-200464210-00005\/METRICS","volume":"64","author":"ES Rovner","year":"2004","unstructured":"Rovner ES. Trospium chloride in the management of overactive bladder. Drugs. 2004;64:2433\u201346. https:\/\/doi.org\/10.2165\/00003495-200464210-00005\/METRICS.","journal-title":"Drugs"},{"key":"3275_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/GUT.35.1.27","volume":"35","author":"T Schmidt","year":"1994","unstructured":"Schmidt T, Widmer R, Pfeiffer A, Kaess H. Effect of the quaternary ammonium compound trospium chloride on 24\u00a0hour jejunal motility in healthy subjects. Gut. 1994;35:27\u201333. https:\/\/doi.org\/10.1136\/GUT.35.1.27.","journal-title":"Gut"},{"key":"3275_CR17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/0016-5085(86)90696-7","volume":"91","author":"D Kumar","year":"1986","unstructured":"Kumar D, Wingate D, Ruckebusch Y. Circadian variation in the propagation velocity of the migrating motor complex. Gastroenterology. 1986;91:926\u201356.","journal-title":"Gastroenterology"},{"key":"3275_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5414\/CPP42543","volume":"42","author":"S Schr\u00f6der","year":"2004","unstructured":"Schr\u00f6der S, Jetter A, Zaigler M, et al. Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. Int J Clin Pharmacol Ther. 2004;42:543\u20139. https:\/\/doi.org\/10.5414\/CPP42543.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3275_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2165\/00003088-200342140-00004","volume":"14","author":"DRP Guay","year":"2003","unstructured":"Guay DRP. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;14:1243\u201386. https:\/\/doi.org\/10.2165\/00003088-200342140-00004.","journal-title":"Clin Pharmacokinet"},{"key":"3275_CR20","first-page":"585","volume":"5","author":"H Albrecht","year":"1983","unstructured":"Albrecht H, Bruhn R, Lorenz D, L\u00fccker PW, Schumacher M. Pupillometry: a non-invasive pharmacokinetic and pharmacodynamic method to study the action of trospium chloride (Spasmo-lyt) on smooth muscle. Methods Find Exp Clin Pharmacol. 1983;5:585\u20137.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"3275_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1517\/14656566.7.10.1373","volume":"7","author":"H Madersbacher","year":"2006","unstructured":"Madersbacher H, Rovner E. Trospium chloride: the European experience. Expert Opin Pharmacother. 2006;7:1373\u201380. https:\/\/doi.org\/10.1517\/14656566.7.10.1373.","journal-title":"Expert Opin Pharmacother"},{"key":"3275_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1756287217708951\/ASSET\/IMAGES\/LARGE\/10.1177_1756287217708951-FIG2.JPEG","volume":"9","author":"D Dahlinger","year":"2017","unstructured":"Dahlinger D, Aslan S, Pietsch M, Frechen S, Fuhr U. Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. Ther Adv Urol. 2017;9:163\u201377. https:\/\/doi.org\/10.1177\/1756287217708951\/ASSET\/IMAGES\/LARGE\/10.1177_1756287217708951-FIG2.JPEG.","journal-title":"Ther Adv Urol"},{"key":"3275_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/J.UCL.2006.06.006","volume":"33","author":"DR Staskin","year":"2006","unstructured":"Staskin DR. Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am. 2006;33:465\u201373. https:\/\/doi.org\/10.1016\/J.UCL.2006.06.006.","journal-title":"Urol Clin North Am"},{"key":"3275_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.clinthera.2005.05.008","volume":"27","author":"D Singh-Franco","year":"2005","unstructured":"Singh-Franco D, Machado C, Tuteja S, Zapantis A. Trospium chloride for the treatment of overactive bladder with urge incontinence. Clin Ther. 2005;27:511\u201330. https:\/\/doi.org\/10.1016\/j.clinthera.2005.05.008.","journal-title":"Clin Ther"},{"key":"3275_CR25","unstructured":"Sandage B, Najarian N, Lasseter K. The effect of liver disease on the pharmacokinetics of trospium chloride. Annual Meetingo of the International Continence Society\u2014Poster Nr 584. 2004."},{"key":"3275_CR26","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1248\/BPB.30.955","volume":"30","author":"H Mizushima","year":"2007","unstructured":"Mizushima H, Kinoshita K, Abe K, Ishizuka H, Yamada Y. Pharmacokinetics\/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats. Biol Pharm Bull. 2007;30:955\u201362. https:\/\/doi.org\/10.1248\/BPB.30.955.","journal-title":"Biol Pharm Bull"},{"key":"3275_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/BF00558247","volume":"35","author":"J Douchamps","year":"1988","unstructured":"Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988;35:515\u201320. https:\/\/doi.org\/10.1007\/BF00558247.","journal-title":"Eur J Clin Pharmacol"},{"key":"3275_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/(SICI)1520-6777(1999)18:5<447::AID-NAU6>3.0.CO;2-Q","volume":"18","author":"P Walter","year":"1999","unstructured":"Walter P, Grosse J, Bihr AM, et al. Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: a pilot study. Neurourol Urodyn. 1999;18:447\u201353. https:\/\/doi.org\/10.1002\/(SICI)1520-6777(1999)18:5%3c447::AID-NAU6%3e3.0.CO;2-Q.","journal-title":"Neurourol Urodyn"},{"key":"3275_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPHARM.2022.121849","author":"J Rahman-Yildir","year":"2022","unstructured":"Rahman-Yildir J, Fischer B, Breitkreutz J. Development of sustained-release drug-loaded intravesical inserts via semi-solid micro-extrusion 3D-printing for bladder targeting. Int J Pharm. 2022. https:\/\/doi.org\/10.1016\/J.IJPHARM.2022.121849.","journal-title":"Int J Pharm"},{"key":"3275_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPHARM.2022.121984","author":"J Rahman-Yildir","year":"2022","unstructured":"Rahman-Yildir J, Wiedey R, Breitkreutz J. Comparative dissolution studies of 3D-printed inserts in a novel biopharmaceutical bladder model. Int J Pharm. 2022. https:\/\/doi.org\/10.1016\/J.IJPHARM.2022.121984.","journal-title":"Int J Pharm"},{"key":"3275_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/J.JCONREL.2013.05.018","volume":"170","author":"M Haupt","year":"2013","unstructured":"Haupt M, Thommes M, Heidenreich A, Breitkreutz J. Lipid-based intravesical drug delivery systems with controlled release of trospium chloride for the urinary bladder. J Control Release. 2013;170:161\u20136. https:\/\/doi.org\/10.1016\/J.JCONREL.2013.05.018.","journal-title":"J Control Release"},{"key":"3275_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00271361\/METRICS","volume":"44","author":"A Pfeiffer","year":"1993","unstructured":"Pfeiffer A, Schmidt T, H\u00f6ller T, et al. Effect of trospium chloride on gastrointestinal motility in humans. Eur J Clin Pharmacol. 1993;44:219\u201323. https:\/\/doi.org\/10.1007\/BF00271361\/METRICS.","journal-title":"Eur J Clin Pharmacol"},{"key":"3275_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/S40261-012-0049-6\/TABLES\/4","volume":"33","author":"MG Oefelein","year":"2013","unstructured":"Oefelein MG, Tong W, Kerr S, Bhasi K, Patel RK, Yu D. Effect of concomitant administration of trospium chloride extended release on the steady-state pharmacokinetics of metformin in healthy adults. Clin Drug Investig. 2013;33:123\u201331. https:\/\/doi.org\/10.1007\/S40261-012-0049-6\/TABLES\/4.","journal-title":"Clin Drug Investig"},{"key":"3275_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000282207","volume":"47","author":"M St\u00f6hrer","year":"1991","unstructured":"St\u00f6hrer M, Bauer P, Giannetti BM, Richter R, Burgd\u00f6rfer H, M\u00fcrtz G. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuriesa multicentre placebo-controlled double-blind trial. Urol Int. 1991;47:138\u201343. https:\/\/doi.org\/10.1159\/000282207.","journal-title":"Urol Int"},{"key":"3275_CR35","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1046\/J.1464-410X.2000.00575.X","volume":"85","author":"L Cardozo","year":"2000","unstructured":"Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. 2000;85:659\u201364. https:\/\/doi.org\/10.1046\/J.1464-410X.2000.00575.X.","journal-title":"BJU Int"},{"key":"3275_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.urology.2005.08.017","volume":"67","author":"D Rudy","year":"2006","unstructured":"Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase\u00a0III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67:275\u201380. https:\/\/doi.org\/10.1016\/j.urology.2005.08.017.","journal-title":"Urology"},{"key":"3275_CR37","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1097\/01.JU.0000127742.73136.0C","volume":"171","author":"N Zinner","year":"2004","unstructured":"Zinner N, Gittelman M, Harris R, Susset J, Kanellos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase\u00a0III trial. J Urol. 2004;171:2311\u20135. https:\/\/doi.org\/10.1097\/01.JU.0000127742.73136.0C.","journal-title":"J Urol"},{"key":"3275_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/J.1464-410X.1995.TB07264.X","volume":"75","author":"H Madersbacher","year":"1995","unstructured":"Madersbacher H, St\u00f6hrer M, Richter R, Burgd\u00f6rfer H, Hachen HJ, M\u00fcrtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol. 1995;75:452\u20136. https:\/\/doi.org\/10.1111\/J.1464-410X.1995.TB07264.X.","journal-title":"Br J Urol"},{"key":"3275_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/sc.2014.113","volume":"52","author":"N Hadiji","year":"2014","unstructured":"Hadiji N, Previnaire JG, Benbouzid R, et al. Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients? Spinal Cord. 2014;52:701\u20135. https:\/\/doi.org\/10.1038\/sc.2014.113.","journal-title":"Spinal Cord"},{"key":"3275_CR40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/S00345-003-0321-8\/METRICS","volume":"20","author":"M Halaska","year":"2003","unstructured":"Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392\u20139. https:\/\/doi.org\/10.1007\/S00345-003-0321-8\/METRICS.","journal-title":"World J Urol"},{"key":"3275_CR41","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000363658","volume":"93","author":"KV Kosilov","year":"2014","unstructured":"Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women. Urol Int. 2014;93:470\u20133. https:\/\/doi.org\/10.1159\/000363658.","journal-title":"Urol Int"},{"key":"3275_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3109\/13685538.2014.951922","volume":"18","author":"K Kosilov","year":"2015","unstructured":"Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Additional correction of OAB symptoms by two anti-muscarinics for men over 50\u00a0years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin. Aging Male. 2015;18:44\u20138. https:\/\/doi.org\/10.3109\/13685538.2014.951922.","journal-title":"Aging Male"},{"key":"3275_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1557988315595692","volume":"10","author":"KV Kosilov","year":"2016","unstructured":"Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Effectiveness of solifenacin and trospium for managing of severe symptoms of overactive bladder in patients with benign prostatic hyperplasia. Am J Mens Health. 2016;10:157\u201363. https:\/\/doi.org\/10.1177\/1557988315595692.","journal-title":"Am J Mens Health"},{"key":"3275_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.5414\/CPP44623","volume":"44","author":"M Menarini","year":"2006","unstructured":"Menarini M, Del Popolo G, Di Benedetto P, et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther. 2006;44:623\u201332. https:\/\/doi.org\/10.5414\/CPP44623.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3275_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-10-15\/FIGURES\/2","volume":"10","author":"RH B\u00f6deker","year":"2010","unstructured":"B\u00f6deker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol. 2010;10:1\u20137. https:\/\/doi.org\/10.1186\/1471-2490-10-15\/FIGURES\/2.","journal-title":"BMC Urol"},{"key":"3275_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.urology.2007.11.008","volume":"71","author":"RR Dmochowski","year":"2008","unstructured":"Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60\u00a0mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008;71:449\u201354. https:\/\/doi.org\/10.1016\/j.urology.2007.11.008.","journal-title":"Urology"},{"key":"3275_CR47","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/J.1742-1241.2009.02189.X","volume":"63","author":"DR Staskin","year":"2009","unstructured":"Staskin DR, Rosenberg MT, Sand PK, Zinner NR, Dmochowski RR. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase\u00a0III trials. Int J Clin Pract. 2009;63:1715\u201323. https:\/\/doi.org\/10.1111\/J.1742-1241.2009.02189.X.","journal-title":"Int J Clin Pract"},{"key":"3275_CR48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/NAU.21018","volume":"30","author":"DA Ginsberg","year":"2011","unstructured":"Ginsberg DA, Oefelein MG, Ellsworth PI. Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase\u00a0III trials. Neurourol Urodyn. 2011;30:563\u20137. https:\/\/doi.org\/10.1002\/NAU.21018.","journal-title":"Neurourol Urodyn"},{"key":"3275_CR49","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/J.1742-1241.2009.02065.X","volume":"63","author":"DR Staskin","year":"2009","unstructured":"Staskin DR, Cardozo L. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. Int J Clin Pract. 2009;63:973\u20136. https:\/\/doi.org\/10.1111\/J.1742-1241.2009.02065.X.","journal-title":"Int J Clin Pract"},{"key":"3275_CR50","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/NAU.20787","volume":"29","author":"MB Chancellor","year":"2010","unstructured":"Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourol Urodyn. 2010;29:551\u20134. https:\/\/doi.org\/10.1002\/NAU.20787.","journal-title":"Neurourol Urodyn"},{"key":"3275_CR51","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/S00192-009-0969-8\/METRICS","volume":"20","author":"PK Sand","year":"2009","unstructured":"Sand PK, Dmochowski RR, Zinner NR, Staskin DR, Appell RA. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:1431\u20138. https:\/\/doi.org\/10.1007\/S00192-009-0969-8\/METRICS.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"3275_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.urology.2010.07.469","volume":"77","author":"SA MacDiarmid","year":"2011","unstructured":"MacDiarmid SA, Ellsworth PI, Ginsberg DA, Oefelein MG, Sussman DO. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology. 2011;77:24\u20139. https:\/\/doi.org\/10.1016\/j.urology.2010.07.469.","journal-title":"Urology"},{"key":"3275_CR53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/J.1464-410X.2010.09519.X","volume":"107","author":"PK Sand","year":"2011","unstructured":"Sand PK, Johnson TM, Rovner ES, Ellsworth PI, Oefelein MG, Staskin DR. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged \u226575\u00a0years) with overactive bladder syndrome. BJU Int. 2011;107:612\u201320. https:\/\/doi.org\/10.1111\/J.1464-410X.2010.09519.X.","journal-title":"BJU Int"},{"key":"3275_CR54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2165\/11586740-000000000-00000\/METRICS","volume":"28","author":"PK Sand","year":"2011","unstructured":"Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011;28:151\u201360. https:\/\/doi.org\/10.2165\/11586740-000000000-00000\/METRICS.","journal-title":"Drugs Aging"},{"key":"3275_CR55","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/NAU.21000","volume":"30","author":"NR Zinner","year":"2011","unstructured":"Zinner NR, Dmochowski RR, Staskin DR, Siami PF, Sand PK, Oefelein MG. Once-daily trospium chloride 60\u00a0mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011;30:1214\u20139. https:\/\/doi.org\/10.1002\/NAU.21000.","journal-title":"Neurourol Urodyn"},{"key":"3275_CR56","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/J.1532-5415.2005.00537.X","volume":"53","author":"GG Kay","year":"2005","unstructured":"Kay GG, Abou-Donia MB, Messer WS, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53:2195\u2013201. https:\/\/doi.org\/10.1111\/J.1532-5415.2005.00537.X.","journal-title":"J Am Geriatr Soc"},{"key":"3275_CR57","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.10639","volume":"54","author":"EK Perry","year":"2003","unstructured":"Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson\u2019s disease related to antimuscarinic drugs. Ann Neurol. 2003;54:235\u20138. https:\/\/doi.org\/10.1002\/ana.10639.","journal-title":"Ann Neurol"},{"key":"3275_CR58","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3233\/JAD-191199","volume":"74","author":"K Richardson","year":"2020","unstructured":"Richardson K, Wharton SB, Grossi CM, et al. Neuropathological correlates of cumulative benzodiazepine and anticholinergic drug use. J Alzheimers Dis. 2020;74:999\u20131009. https:\/\/doi.org\/10.3233\/JAD-191199.","journal-title":"J Alzheimers Dis"},{"key":"3275_CR59","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1093\/cercor\/bhy214","volume":"29","author":"JP Chhatwal","year":"2019","unstructured":"Chhatwal JP, Schultz AP, Hedden T, et al. Anticholinergic amnesia is mediated by alterations in human network connectivity architecture. Cereb Cortex. 2019;29:3445\u201356. https:\/\/doi.org\/10.1093\/cercor\/bhy214.","journal-title":"Cereb Cortex"},{"key":"3275_CR60","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","volume":"18","author":"B Welk","year":"2021","unstructured":"Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol. 2021;18:686\u2013700. https:\/\/doi.org\/10.1038\/s41585-021-00504-x.","journal-title":"Nat Rev Urol"},{"key":"3275_CR61","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. JAMA Intern Med. 2019;179:1084. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0677.","journal-title":"JAMA Intern Med"},{"key":"3275_CR62","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/S11934-004-0068-9\/METRICS","volume":"5","author":"HG Madersbacher","year":"2004","unstructured":"Madersbacher HG. Confusion about measuring central nervous system effects. Curr Urol Rep. 2004;5:442\u20136. https:\/\/doi.org\/10.1007\/S11934-004-0068-9\/METRICS.","journal-title":"Curr Urol Rep"},{"key":"3275_CR63","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/DMD.109.027144","volume":"37","author":"J Geyer","year":"2009","unstructured":"Geyer J, Gavrilova O, Petzinger E. The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos. 2009;37:1371\u20134. https:\/\/doi.org\/10.1124\/DMD.109.027144.","journal-title":"Drug Metab Dispos"},{"key":"3275_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/S00345-011-0803-Z\/TABLES\/1","volume":"31","author":"J Kranz","year":"2013","unstructured":"Kranz J, Petzinger E, Geyer J. Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World J Urol. 2013;31:219\u201324. https:\/\/doi.org\/10.1007\/S00345-011-0803-Z\/TABLES\/1.","journal-title":"World J Urol"},{"key":"3275_CR65","first-page":"1362","volume":"37","author":"P Langguth","year":"1987","unstructured":"Langguth P, Mutschler E. Lipophilisation of hydrophilic compounds. Consequences on transepidermal and intestinal transport of trospium chloride. Arzneimittelforschung. 1987;37:1362\u20136.","journal-title":"Arzneimittelforschung"},{"key":"3275_CR66","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/J.1532-5415.2010.02988.X","volume":"58","author":"D Staskin","year":"2010","unstructured":"Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc. 2010;58:1618\u20139. https:\/\/doi.org\/10.1111\/J.1532-5415.2010.02988.X.","journal-title":"J Am Geriatr Soc"},{"key":"3275_CR67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF00191165\/METRICS","volume":"47","author":"A Pietzko","year":"1994","unstructured":"Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol. 1994;47:337\u201343. https:\/\/doi.org\/10.1007\/BF00191165\/METRICS.","journal-title":"Eur J Clin Pharmacol"},{"key":"3275_CR68","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/00912700122010528","volume":"41","author":"A Todorova","year":"2001","unstructured":"Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41:636\u201344. https:\/\/doi.org\/10.1177\/00912700122010528.","journal-title":"J Clin Pharmacol"},{"key":"3275_CR69","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s12603-009-0196-5","volume":"13","author":"AT Isik","year":"2009","unstructured":"Isik AT, Celik T, Bozoglu E, Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging. 2009;13:672\u20136. https:\/\/doi.org\/10.1007\/s12603-009-0196-5.","journal-title":"J Nutr Health Aging"},{"key":"3275_CR70","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5764-DN-2022-0053","author":"A Naseri","year":"2023","unstructured":"Naseri A, Sadigh-Eteghad S, Seyedi-Sahebari S, Hosseini MS, Hajebrahimi S, Salehi-Pourmehr H. Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis. Dement Neuropsychol. 2023. https:\/\/doi.org\/10.1590\/1980-5764-DN-2022-0053.","journal-title":"Dement Neuropsychol"},{"key":"3275_CR71","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/S11934-004-0064-0\/METRICS","volume":"5","author":"DR Staskin","year":"2004","unstructured":"Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep. 2004;5:423\u20136. https:\/\/doi.org\/10.1007\/S11934-004-0064-0\/METRICS.","journal-title":"Curr Urol Rep"},{"key":"3275_CR72","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/J.1742-1241.2010.02433.X","volume":"64","author":"D Staskin","year":"2010","unstructured":"Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64:1294\u2013300. https:\/\/doi.org\/10.1111\/J.1742-1241.2010.02433.X.","journal-title":"Int J Clin Pract"},{"key":"3275_CR73","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/SPV.0000000000000374","volume":"23","author":"EJ Geller","year":"2017","unstructured":"Geller EJ, Dumond JB, Bowling JM, et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Med Reconstr Surg. 2017;23:118\u201323. https:\/\/doi.org\/10.1097\/SPV.0000000000000374.","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"3275_CR74","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/15569527.2017.1289219","volume":"36","author":"AR Turkoglu","year":"2017","unstructured":"Turkoglu AR, Parmak Yener N, et al. Effect of trospium chloride therapy on intraocular pressure and tear secretion in overactive bladder patients. Cutan Ocul Toxicol. 2017;36:331\u20135. https:\/\/doi.org\/10.1080\/15569527.2017.1289219.","journal-title":"Cutan Ocul Toxicol"},{"key":"3275_CR75","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/J.CLINTHERA.2005.01.006","volume":"27","author":"GG Kay","year":"2005","unstructured":"Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther. 2005;27:127\u201338. https:\/\/doi.org\/10.1016\/J.CLINTHERA.2005.01.006.","journal-title":"Clin Ther"},{"key":"3275_CR76","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/14651858.CD003781.PUB3","volume":"5","author":"A Stoniute","year":"2023","unstructured":"Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar M. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023;5:421\u20132. https:\/\/doi.org\/10.1002\/14651858.CD003781.PUB3.","journal-title":"Cochrane Database Syst Rev"},{"key":"3275_CR77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/RRU.S185278","volume":"11","author":"S Murgas","year":"2019","unstructured":"Murgas S, Adolf D. Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany. Res Rep Urol. 2019;11:9\u201313. https:\/\/doi.org\/10.2147\/RRU.S185278.","journal-title":"Res Rep Urol"},{"key":"3275_CR78","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/nau.25532","volume":"43","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. Neurourol Urodyn. 2024;43:1742\u201352. https:\/\/doi.org\/10.1002\/nau.25532.","journal-title":"Neurourol Urodyn"},{"key":"3275_CR79","unstructured":"Harding C, Lapitan M, Arlandis S, et al. EAU guidelines on management of non-neurogenic female lower urinary tract symptoms. European Association of Urology; 2025. https:\/\/uroweb.org\/guidelines\/non-neurogenic-female-luts\/chapter\/disease-management. Accessed 29 May 2025."},{"key":"3275_CR80","unstructured":"Cornu J, Gacci M, Hashim H, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS). European Association of Urology; 2025. https:\/\/uroweb.org\/guidelines\/management-of-non-neurogenic-male-luts\/chapter\/disease-management. Accessed 29 May 2025."},{"key":"3275_CR81","unstructured":"Blok B, Castro-Diaz D, Del Popolo G, et al. EAU guidelines on neuro-urology. European Association of Urology; 2025. https:\/\/uroweb.org\/guidelines\/neuro-urology\/chapter\/the-guideline. Accessed 29 May 2025."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03275-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03275-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03275-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:01:53Z","timestamp":1757206913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03275-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3275"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03275-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jos\u00e9 C. Truzzi: speaker\/board advisor for Coloplast Brazil, Adium Brasil; Marair G.F. Sartori: speaker for Apsen Farmac\u00eautica SA, and Astellas Pharma Inc.; Vit\u00f3rio L. Kemp: Medical Manager for Apsen Farmac\u00eautica SA; The referred companies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any novel studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}